{"id":3304,"date":"2024-04-24T16:19:42","date_gmt":"2024-04-24T13:19:42","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3304"},"modified":"2024-04-24T16:22:57","modified_gmt":"2024-04-24T13:22:57","slug":"menarini-turkiye-uretim-kapasitesini-surekli-artirarak-yerel-uretim-alaninda-attigi-adimlari-guclendiriyor","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3304","title":{"rendered":"Menarini T\u00fcrkiye \u00dcretim Kapasitesini S\u00fcrekli Art\u0131rarak Yerel \u00dcretim Alan\u0131nda Att\u0131\u011f\u0131 Ad\u0131mlar\u0131 G\u00fc\u00e7lendiriyor"},"content":{"rendered":"\n

D\u00fcnyadaki 18 \u00fcretim tesisinden biri olan \u0130stanbul’daki fabrikas\u0131nda 2023 y\u0131l\u0131nda 100 milyon kutunun \u00fczerinde \u00fcretim ger\u00e7ekle\u015ftirerek, \u00fcretimde T\u00fcrkiye\u2019nin 4.\u00a0 firmas\u0131 olman\u0131n gururunu ya\u015fayan\u00a0 Menarini T\u00fcrkiye\u2019nin Teknik Operasyonlar Direkt\u00f6r\u00fc ve META B\u00f6lgesi MS&T Lideri M. Ahmet \u015eencan, \u015firketin \u00fcretim s\u00fcre\u00e7leri hakk\u0131ndaki sorular\u0131m\u0131z\u0131 yan\u0131tlad\u0131.\u00a0<\/strong><\/p>\n\n\n\n

Sizi biraz tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Gazi \u00dcniversitesi Eczac\u0131l\u0131k Fak\u00fcltesi mezunuyum. Y\u00fcksek lisans e\u011fitimimi 1995 y\u0131l\u0131nda Gazi \u00dcniversitesi Eczac\u0131l\u0131k, Farmas\u00f6tik Teknoloji B\u00f6l\u00fcm\u00fc\u2019nde tamamlad\u0131m. Sekt\u00f6re \u0130E Ulagay \u0130la\u00e7 San. ve T\u00fcrk A.\u015e.\u2019de ba\u015flad\u0131m. S\u0131ras\u0131yla Ar-Ge \u015eefi, Ar-Ge M\u00fcd\u00fcr\u00fc, Non-Steril \u00dcr\u00fcnler \u00dcretim M\u00fcd\u00fcr\u00fc olarak 8 y\u0131l\u0131 a\u015fk\u0131n bir s\u00fcre g\u00f6rev ald\u0131m. Ard\u0131ndan yine ila\u00e7 sekt\u00f6r\u00fcnde farkl\u0131 firma ve pozisyonlarda 20 y\u0131l kariyerime devam ettim. 2024 y\u0131l\u0131 ba\u015f\u0131ndan itibaren de kariyerime Menarini T\u00fcrkiye Teknik Operasyonlar Direkt\u00f6r\u00fc ve META B\u00f6lgesi MS&T Lideri olarak devam ediyorum.<\/p>\n\n\n\n

Menarini\u2019nin \u00fcretim hatt\u0131n\u0131 bize biraz anlat\u0131r m\u0131s\u0131n\u0131z? \u00dcretim tesisiniz y\u0131ll\u0131k \u00fcretim kapasiteniz <\/strong>ve \u00fcretim teknolojinizden biraz s\u00f6z eder misiniz?<\/strong><\/p>\n\n\n\n

Menarini\u2019nin d\u00fcnyadaki 18 \u00fcretim tesisinden biri olan \u0130stanbul’daki fabrikam\u0131zda, T\u00fcrkiye ve b\u00f6lge \u00fclkelerine 300’den fazla \u00fcr\u00fcn ve tedavi se\u00e7ene\u011fi sunuyoruz.  22.000 m2<\/sup> alana sahip Topkap\u0131 \u00dcretim Tesisi ve Had\u0131mk\u00f6y Depo b\u00fcnyemizde toplam 454 \u00e7al\u0131\u015fan\u0131m\u0131z ile bir\u00e7ok farmas\u00f6tik formlar\u0131 \u00fcretmekteyiz. <\/p>\n\n\n\n

Lokal \u00fcretimimizle T\u00fcrkiye’nin en h\u0131zl\u0131 b\u00fcy\u00fcyen ila\u00e7 firmalar\u0131ndan biri haline geldik. 1955 y\u0131l\u0131nda kurulan, g\u00fcncel reg\u00fclasyonlar do\u011frultusunda d\u00fczenlenen ve yenilenen teknolojik ekipmanlarla kalite standartlar\u0131n\u0131n en \u00fcst seviyede uyguland\u0131\u011f\u0131 bu tesislerde, g\u00fcn\u00fcm\u00fczde y\u0131lda 100 milyon kutu \u00fczerinde \u00fcretim ger\u00e7ekle\u015ftiriyoruz. 2023 y\u0131l\u0131nda %86 kapasite kullan\u0131m oran\u0131na ula\u015ft\u0131k. Fabrikam\u0131z d\u0131\u015f\u0131nda ihtiya\u00e7lar\u0131m\u0131z\u0131 kar\u015f\u0131lamak i\u00e7in kontratl\u0131 olarak di\u011fer firmalarda yapt\u0131rd\u0131\u011f\u0131m\u0131z \u00fcretimle 2023 y\u0131l\u0131nda 125 milyon kutuya varan \u00fcretim ger\u00e7ekle\u015ftirdik.<\/p>\n\n\n\n

\u00dcretim kapasitemizi s\u00fcrekli art\u0131r\u0131yoruz, yenilenen teknolojik ekipmanlar ve teknoloji transferleri sayesinde yerel \u00fcretim alan\u0131nda att\u0131\u011f\u0131m\u0131z ad\u0131mlar\u0131m\u0131z\u0131 g\u00fc\u00e7lendiriyoruz. \u0130la\u00e7 sanayinde \u00fcr\u00fcn kalitesinin hayati \u00f6neme sahip oldu\u011funun bilinciyle bug\u00fcnlere geldik. Y\u00fcksek teknolojiye sahip \u00fcretim tesislerimiz ve nitelikli insan kayna\u011f\u0131m\u0131zla \u00e7ok daha fazla insana kaliteli ve ula\u015f\u0131labilir \u00fcr\u00fcn ve hizmet sunmak i\u00e7in \u00e7al\u0131\u015f\u0131yoruz. Ayr\u0131ca stratejik s\u00fcrd\u00fcr\u00fclebilirlik planlar\u0131m\u0131z \u00e7er\u00e7evesinde \u00fcretim s\u00fcre\u00e7lerimizin \u00e7evresel etkisini; do\u011fal kaynak kullan\u0131m\u0131, at\u0131klar\u0131n y\u00f6netimi, karbon ayak izini azaltma, enerji kullan\u0131m\u0131 ve verimlilik konular\u0131nda belirledi\u011fimiz k\u0131sa ve uzun vadeli hedefler ile takip ederek gerekli \u00e7al\u0131\u015fmalar\u0131 yap\u0131yoruz.<\/p>\n\n\n\n

Hangi tedavi alanlar\u0131na y\u00f6nelik \u00fcr\u00fcnler \u00fcretiyorsunuz?<\/strong><\/p>\n\n\n\n

<\/a>Menarini T\u00fcrkiye olarak geni\u015f bir \u00fcr\u00fcn portf\u00f6y\u00fcm\u00fcz bulunuyor. Farmakolojik grup olarak kardiyovask\u00fcler, kas iskelet sistemi, solunum sistemi, enfeksiyon, n\u00f6rolojik, metabolik hastal\u0131klar, vitamin ve mineraller, gastrointestinal, dermatolojik ila\u00e7lar, alerji ve a\u011fr\u0131 alanlar\u0131na y\u00f6nelik yenilik\u00e7i \u00fcr\u00fcnler \u00fcretiyoruz. T\u00fcketici sa\u011fl\u0131\u011f\u0131 taraf\u0131nda ise bir\u00e7ok alanda farkl\u0131 ihtiyaca y\u00f6nelik yenilik\u00e7i \u00fcr\u00fcnlerimiz, portf\u00f6y\u00fcm\u00fczde bulunan takviye edici g\u0131dalar ve farkl\u0131 nitelikte t\u00fcketici sa\u011fl\u0131\u011f\u0131 \u00fcr\u00fcnlerimizle ya\u015fam kalitesini destekleyen \u00e7\u00f6z\u00fcmler sunuyoruz. <\/p>\n\n\n\n

\u0130stanbul\u2019daki \u00fcretim tesisimizde \u00fclkemizde piyasaya sunulan \u00fcr\u00fcnlerimizin neredeyse tamam\u0131n\u0131 \u00fcretiyoruz. Tesisimiz, mamul ila\u00e7 \u00fcretiminin yap\u0131ld\u0131\u011f\u0131 \u00fc\u00e7 ayr\u0131 \u00fcretim \u00fcnitesinden olu\u015fuyor. Bu \u00fc\u00e7 \u00fcniteden ikisinde beta-laktam grubu \u00fcr\u00fcnler, penisilin ve sefalosporin bazl\u0131 olmayan non-betalaktam \u00fcr\u00fcnler \u00fcretiyoruz. <\/p>\n\n\n\n

Beta-laktam grubu \u00fcniteleri, di\u011fer \u00fcretim alanlar\u0131ndan ve birbirlerinden tamam\u0131yla ayr\u0131lm\u0131\u015f sadece penisilin veya sefalosporin bazl\u0131 antibiyotik \u00fcr\u00fcnler \u00fcretilen alanlard\u0131r. Ba\u011f\u0131ms\u0131z penisilin \u00fcnitelerinde birbirinden de ayr\u0131lm\u0131\u015f bir \u015fekilde penisilin bazl\u0131 oral kat\u0131 ve penisilin bazl\u0131 steril toz \u00fcr\u00fcnler; ba\u011f\u0131ms\u0131z sefalosporin \u00fcnitesinde ise sadece sefalosporin bazl\u0131 steril toz \u00fcr\u00fcnler \u00fcretiyoruz. \u00dc\u00e7\u00fcnc\u00fc \u00fcretim \u00fcnitemizde ise penisilin ve sefalosporin gruplar\u0131ndan olmayan \u00fcr\u00fcnlerden olu\u015fan oral kat\u0131 ve k\u00fc\u00e7\u00fck hacimli steril s\u0131v\u0131 formlar (ampul veya damla) \u00fcretiliyor.<\/p>\n\n\n\n

Yerli ila\u00e7 \u00fcretiminin bir \u00fclke i\u00e7in \u00f6nemini ve T\u00fcrkiye ekonomisi i\u00e7in Menarini\u2019nin katk\u0131s\u0131n\u0131 de\u011ferlendirecek olursan\u0131z neler s\u00f6ylersiniz?<\/strong><\/p>\n\n\n\n

\u00dclkemizde ila\u00e7 sekt\u00f6r\u00fc ilk kurulan sekt\u00f6rlerden birisi olmas\u0131na ra\u011fmen T\u00fcrkiye\u2019nin ila\u00e7ta d\u0131\u015fa ba\u011f\u0131ml\u0131l\u0131\u011f\u0131 h\u00e2l\u00e2 devam etmektedir. Menarini, yerli \u00fcretime destek olmak ve T\u00fcrkiye piyasas\u0131nda yerini almak i\u00e7in 2001 y\u0131l\u0131nda \u0130E Ulagay firmas\u0131n\u0131 sat\u0131n alarak T\u00fcrkiye ila\u00e7 sekt\u00f6r\u00fcne girmi\u015ftir. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n lokalizasyon projesine gereken deste\u011fi vererek bir\u00e7ok \u00fcr\u00fcn\u00fc T\u00fcrkiye tesisinde \u00fcretmekteyiz. Avrupa ve d\u00fcnya standartlar\u0131ndaki kalite anlay\u0131\u015f\u0131m\u0131zla 2023 y\u0131l\u0131nda 100 milyon kutuyu a\u015farak \u00fcretimde T\u00fcrkiye\u2019nin 4. firmas\u0131 olma gururunu ya\u015f\u0131yoruz.<\/p>\n\n\n\n

T\u00fcrkiye\u2019de \u00fcretilen \u00fcr\u00fcnlerinizin ihracat\u0131n\u0131 ger\u00e7ekle\u015ftiriyor musunuz? H\u00e2lihaz\u0131rda ihracat yapt\u0131\u011f\u0131n\u0131z \u00fclkeler hangileri ve y\u0131ll\u0131k ihracat rakamlar\u0131n\u0131z nedir?<\/strong><\/p>\n\n\n\n

2012 y\u0131l\u0131ndan itibaren T\u00fcrkiye\u2019den yakla\u015f\u0131k 10\u2019dan fazla \u00fclkeye ihracat ger\u00e7ekle\u015ftiriyoruz. Toplam 3,5 milyon kutu ile aktif ihracatlar\u0131m\u0131z\u0131n s\u00fcrd\u00fc\u011f\u00fc \u00fclkeler; Azerbaycan, G\u00fcrcistan, T\u00fcrkmenistan, Kosova, Makedonya, Cezayir, Afganistan, Bosna-Hersek, Irak, Yemen, Polonya\u2019d\u0131r. Yeni ruhsatland\u0131rma \u00e7al\u0131\u015fmalar\u0131m\u0131z da t\u00fcm h\u0131z\u0131yla devam etmektedir.<\/p>\n\n\n\n

\u00dcretim kapasitesinin art\u0131r\u0131lmas\u0131 konusunda yak\u0131n gelecekte yeni yat\u0131r\u0131mlar planlan\u0131yor mu? K\u0131sa ve uzun vadedeki hedefleriniz neler?<\/strong><\/p>\n\n\n\n

Menarini T\u00fcrkiye, pazar\u0131nda ula\u015ft\u0131\u011f\u0131 sat\u0131\u015f rakamlar\u0131n\u0131 kar\u015f\u0131layabilmek i\u00e7in kendi tesisindeki 100 milyon kutuluk kapasitede tam dolulu\u011fa ula\u015fm\u0131\u015f durumdad\u0131r. Artan ihtiya\u00e7lar\u0131 i\u00e7in ilk planda kontratl\u0131 \u00fcretimler yapt\u0131rarak ihtiya\u00e7lar\u0131n\u0131 kar\u015f\u0131lamaktad\u0131r. Bunun yan\u0131 s\u0131ra yeni yat\u0131r\u0131mlarla tesisinde modernize \u00e7al\u0131\u015fmalar\u0131n\u0131 s\u00fcrd\u00fcrmektedir. Ayr\u0131ca Menarini T\u00fcrkiye, pazar\u0131ndaki artan pay\u0131yla ihtiyac\u0131 olan kapasiteler i\u00e7in yeni tesis planlar\u0131n\u0131 da haz\u0131rlamaktad\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

D\u00fcnyadaki 18 \u00fcretim tesisinden biri olan \u0130stanbul’daki fabrikas\u0131nda 2023 y\u0131l\u0131nda 100 milyon kutunun \u00fczerinde \u00fcretim ger\u00e7ekle\u015ftirerek, \u00fcretimde T\u00fcrkiye\u2019nin 4.\u00a0 firmas\u0131 olman\u0131n gururunu ya\u015fayan\u00a0 Menarini T\u00fcrkiye\u2019nin Teknik Operasyonlar Direkt\u00f6r\u00fc ve META B\u00f6lgesi MS&T Lideri M. Ahmet \u015eencan, \u015firketin \u00fcretim s\u00fcre\u00e7leri hakk\u0131ndaki sorular\u0131m\u0131z\u0131 yan\u0131tlad\u0131.\u00a0<\/p>\n","protected":false},"author":1,"featured_media":3306,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3304"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3304"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3304\/revisions"}],"predecessor-version":[{"id":3307,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3304\/revisions\/3307"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3306"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}